ACIP recommendations for meningococcal ACWY and meningococcal B vaccines in children and adults with asplenia or hyposplenia33,34,37,38,51
| Age at first dose . | Timing of first dose of meningococcal vaccine . | Total doses of meningococcal vaccine . | Interval between meningococcal vaccines . | Revaccination . |
|---|---|---|---|---|
| MenACWY-CRM (MENVEO) | ||||
| 8 wk | — | 4-dose series | 2-mo, 2-mo, 6-mo intervals | Revaccinate 3 y after primary series; additional boosters every 5 y if risk remains |
| 7-23 mo | — | 2-dose series | 12-wk interval and second dose at ≥12 mo of age | Revaccinate 3 y after primary series; additional boosters every 5 y if risk remains |
| ≥24 mo | — | 2-dose series | 8-wk interval | Revaccinate 3 y after primary series if most recent dose given before age 7 y; additional boosters every 5 y if risk remains |
| MenACWY-D (Menactra) | ||||
| 9-23 mo | Do not administer, because of immune interference with PCV13 | |||
| ≥24 mo | Administer >4 wk after completion of PCV13 series | 2-dose series | 8-wk interval | Revaccinate 3 y after primary series; additional boosters every 5 y if risk remains |
| MenB-4C (BEXSERO)* | ||||
| ≥10 y | — | 2-dose series | 1-mo interval | Revaccinate 1 y after primary series and revaccinate every 2-3 y if risk remains† |
| MenB-FHbp (Trumenba)* | ||||
| ≥10 y | — | 3-dose series | 1-mo, 4-mo intervals | Revaccinate 1 y after primary series and revaccinate every 2-3 y if risk remains† |
| Age at first dose . | Timing of first dose of meningococcal vaccine . | Total doses of meningococcal vaccine . | Interval between meningococcal vaccines . | Revaccination . |
|---|---|---|---|---|
| MenACWY-CRM (MENVEO) | ||||
| 8 wk | — | 4-dose series | 2-mo, 2-mo, 6-mo intervals | Revaccinate 3 y after primary series; additional boosters every 5 y if risk remains |
| 7-23 mo | — | 2-dose series | 12-wk interval and second dose at ≥12 mo of age | Revaccinate 3 y after primary series; additional boosters every 5 y if risk remains |
| ≥24 mo | — | 2-dose series | 8-wk interval | Revaccinate 3 y after primary series if most recent dose given before age 7 y; additional boosters every 5 y if risk remains |
| MenACWY-D (Menactra) | ||||
| 9-23 mo | Do not administer, because of immune interference with PCV13 | |||
| ≥24 mo | Administer >4 wk after completion of PCV13 series | 2-dose series | 8-wk interval | Revaccinate 3 y after primary series; additional boosters every 5 y if risk remains |
| MenB-4C (BEXSERO)* | ||||
| ≥10 y | — | 2-dose series | 1-mo interval | Revaccinate 1 y after primary series and revaccinate every 2-3 y if risk remains† |
| MenB-FHbp (Trumenba)* | ||||
| ≥10 y | — | 3-dose series | 1-mo, 4-mo intervals | Revaccinate 1 y after primary series and revaccinate every 2-3 y if risk remains† |
Use same product for all doses in a series
†MenB booster doses now recommended for person ≥ 10 y with asplenia as of June 2019.